Nektar to pursue anticancer alone as positive Phase II data keep rolling in
This article was originally published in Scrip
Executive Summary
Nektar Therapeutics has decided to continue developing the cancer treatment NKTR-102 by itself instead of seeking a partner, with the potential of huge upside if the drug makes it to market.